3-Chloro-Cinnamic Acid

3-Chloro-Cinnamic Acid

SCHEMBL79591

O=C(O)/C=C/c1cccc(Cl)c1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.76
CYP2C9 P11712 3/20 0.76
MAOB P27338 5/20 0.70
NPSR1 Q6W5P4 1/20 0.62
HDAC3 O15379 2/20 0.61
HDAC4 P56524 2/20 0.61
HDAC1 Q13547 2/20 0.61
HDAC7 Q8WUI4 2/20 0.61
HDAC2 Q92769 2/20 0.61
HDAC10 Q969S8 2/20 0.61
HDAC11 Q96DB2 2/20 0.61
HDAC8 Q9BY41 2/20 0.61
HDAC6 Q9UBN7 2/20 0.61
HDAC9 Q9UKV0 2/20 0.61
HDAC5 Q9UQL6 2/20 0.61
TNKS O95271 1/20 0.61
HCAR2 Q8TDS4 1/20 0.61
TNKS2 Q9H2K2 1/20 0.61
MAOA P21397 3/20 0.58
CYP2D6 P10635 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Chloro-Cinnamic Acid SCHEMBL79592 1.00 CYP1A2 (0.76) CYP1A2CYP2C9MAOBNPSR1HDAC3
3-Chloro-Cinnamic Acid SCHEMBL22396853 1.00 CYP1A2 (0.76) CYP1A2CYP2C9MAOBNPSR1HDAC3
3-Chloro-Cinnamic Acid SCHEMBL11469853 0.98 CYP1A2 (0.73) CYP1A2CYP2C9MAOBNPSR1HDAC3
3-Chloro-Cinnamic Acid SCHEMBL9632314 0.98 CYP1A2 (0.73) CYP1A2CYP2C9MAOBNPSR1HDAC3
3-Chloro-Cinnamic Acid SCHEMBL7753489 0.87 MAOB (0.60) CYP1A2CYP2C9MAOBNPSR1HDAC3
SCHEMBL11844491 0.87 CYP1A2 (0.64) CYP1A2CYP2C9MAOBNPSR1MAOA
SCHEMBL11851984 0.87 CYP1A2 (0.64) CYP1A2CYP2C9MAOBNPSR1MAOA
SCHEMBL31553466 0.86 CYP1A2 (1.00) CYP1A2CYP2C9MAOBNPSR1MAOA
SCHEMBL22596713 0.86 CYP1A2 (0.79) CYP1A2CYP2C9MAOBNPSR1MAOA
SCHEMBL5598564 0.86 CYP1A2 (1.00) CYP1A2CYP2C9MAOBNPSR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497636-B2 Recombinant Saccharomyces cerevisiae cells for cannabinoid production NATIONAL UNIVERSITY OF SINGAPORE (SG) 2025-12-16 US claimed
CN-115594675-B Beta-carbalin-cinnamic acid skeleton derivative and preparation method and application thereof 西安医学院 2024-01-30 CN claimed
CN-115594675-A Beta-carbalin-cinnamic acid skeleton derivative and preparation method and application thereof 西安医学院(CN) 2023-01-13 CN claimed
CN-115260176-A Pyrazole amide derivative containing oxazole group and preparation method and application thereof 安徽农业大学 2022-11-01 CN claimed
CN-112521910-B Preparation method of high-strength bio-based adhesive for sponge 合肥学院 2022-07-12 CN claimed
CN-112521910-A Preparation method of high-strength bio-based adhesive for sponge 合肥学院 2021-03-19 CN claimed
CN-109265458-B Matrine-based antitumor drug compound 中国医学科学院药用植物研究所 2020-09-15 CN claimed
CN-109265458-A A kind of antineoplastic compounds based on matrine 中国医学科学院药用植物研究所 2019-01-25 CN claimed
EP-1526584-B1 Method of forming electroluminescent semiconducting nanocrystal patterned layer for an organic-inorganic hybrid electroluminescent devices, and organic-inorganic hybrid electroluminescent device using the same. SAMSUNG ELECTRONICS CO LTD (KR) 2017-06-14 EP claimed
EP-1429768-B1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA (DE) 2016-11-16 EP claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-1526584-A2 Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same Samsung Electronics Co., Ltd (KR) 2005-04-27 EP claimed
US-20030130300-A1 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 US claimed
EP-1282680-A1 COMPOSITIONS COMPRISING CYCLODEXTRIN THE PROCTER & GAMBLE COMPANY (US) 2003-02-12 EP claimed
US-6503413-B2 Polyalkylene polysiloxane, buffering agent, aqueous carrier THE PROCTER & GAMBLE COMPANY 2003-01-07 US claimed
EP-1255806-A1 STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS THE PROCTER & GAMBLE COMPANY (US) 2002-11-13 EP claimed
US-20020011584-A1 Stable, aqueous compositions for treating surfaces, especially fabrics THE PROCTOR & GAMBLE COMPANY 2002-01-31 US claimed
US-20020010154-A1 Compositions comprising cyclodextrin THE PROCTER & GAMBLE COMPANY 2002-01-24 US claimed
WO-2001088076-A1 COMPOSITIONS COMPRISING CYCLODEXTRIN THE PROCTER & GAMBLE COMPANY (US) 2001-11-22 WO claimed
WO-2001060961-A1 STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS THE PROCTER & GAMBLE COMPANY (US) 2001-08-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010154-A1 Compositions comprising cyclodextrin FFAR4, FRG1, FGB CYP1A2 2261/4885CYP2C9 269/4885MAOB 3237/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 CYP1A2 968/4885CYP2C9 330/4885MAOB 1285/4885
US-20030130300-A1 Respiratory system disorders; synergistic mixtures ADRB3, ADRB1, CHRM3 CYP1A2 592/4885CYP2C9 1672/4885MAOB 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.